92 related articles for article (PubMed ID: 17890857)
1. The selective TP receptor antagonist, S18886 (terutroban), attenuates renal damage in the double transgenic rat model of hypertension.
Sebeková K; Ramuscak A; Boor P; Heidland A; Amann K
Am J Nephrol; 2008; 28(1):47-53. PubMed ID: 17890857
[TBL] [Abstract][Full Text] [Related]
2. Renal effects of S18886 (Terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes.
Sebeková K; Eifert T; Klassen A; Heidland A; Amann K
Diabetes; 2007 Apr; 56(4):968-74. PubMed ID: 17267764
[TBL] [Abstract][Full Text] [Related]
3. Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban).
van der Hoorn JW; Jukema JW; Bekkers ME; Princen HM; Corda S; Emeis JJ; Steendijk P
Crit Care Med; 2008 Sep; 36(9):2576-82. PubMed ID: 18679128
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
Fiebeler A; Nussberger J; Shagdarsuren E; Rong S; Hilfenhaus G; Al-Saadi N; Dechend R; Wellner M; Meiners S; Maser-Gluth C; Jeng AY; Webb RL; Luft FC; Muller DN
Circulation; 2005 Jun; 111(23):3087-94. PubMed ID: 15939810
[TBL] [Abstract][Full Text] [Related]
5. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice.
Xu S; Jiang B; Maitland KA; Bayat H; Gu J; Nadler JL; Corda S; Lavielle G; Verbeuren TJ; Zuccollo A; Cohen RA
Diabetes; 2006 Jan; 55(1):110-9. PubMed ID: 16380483
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes.
Mervaala E; Müller DN; Park JK; Dechend R; Schmidt F; Fiebeler A; Bieringer M; Breu V; Ganten D; Haller H; Luft FC
Hypertension; 2000 Jan; 35(1 Pt 2):360-6. PubMed ID: 10642325
[TBL] [Abstract][Full Text] [Related]
7. Complement activation in angiotensin II-induced organ damage.
Shagdarsuren E; Wellner M; Braesen JH; Park JK; Fiebeler A; Henke N; Dechend R; Gratze P; Luft FC; Muller DN
Circ Res; 2005 Sep; 97(7):716-24. PubMed ID: 16109917
[TBL] [Abstract][Full Text] [Related]
8. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.
Park JK; Müller DN; Mervaala EM; Dechend R; Fiebeler A; Schmidt F; Bieringer M; Schäfer O; Lindschau C; Schneider W; Ganten D; Luft FC; Haller H
Kidney Int; 2000 Oct; 58(4):1420-30. PubMed ID: 11012877
[TBL] [Abstract][Full Text] [Related]
9. Thromboxane A2/prostaglandin H2 receptor activation mediates angiotensin II-induced postischemic neovascularization.
Michel F; Silvestre JS; Waeckel L; Corda S; Verbeuren T; Vilaine JP; Clergue M; Duriez M; Levy BI
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):488-93. PubMed ID: 16385086
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
Pilz B; Shagdarsuren E; Wellner M; Fiebeler A; Dechend R; Gratze P; Meiners S; Feldman DL; Webb RL; Garrelds IM; Jan Danser AH; Luft FC; Müller DN
Hypertension; 2005 Sep; 46(3):569-76. PubMed ID: 16103264
[TBL] [Abstract][Full Text] [Related]
11. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study.
Viles-Gonzalez JF; Fuster V; Corti R; Valdiviezo C; Hutter R; Corda S; Anand SX; Badimon JJ
Eur Heart J; 2005 Aug; 26(15):1557-61. PubMed ID: 15734766
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Park JK; Mervaala EM; Muller DN; Menne J; Fiebeler A; Luft FC; Haller H
J Hypertens; 2009 Mar; 27(3):599-605. PubMed ID: 19262227
[TBL] [Abstract][Full Text] [Related]
13. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Vilahur G; Casaní L; Badimon L
Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II formation in the kidney and nephrosclerosis in Ren-2 hypertensive rats.
Hartner A; Porst M; Klanke B; Cordasic N; Veelken R; Hilgers KF
Nephrol Dial Transplant; 2006 Jul; 21(7):1778-85. PubMed ID: 16522658
[TBL] [Abstract][Full Text] [Related]
15. Is there a relationship between blood pressure and intraocular pressure? An experimental study in hypertensive rats.
Vaajanen A; Mervaala E; Oksala O; Vapaatalo H
Curr Eye Res; 2008 Apr; 33(4):325-32. PubMed ID: 18398707
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
[TBL] [Abstract][Full Text] [Related]
17. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus.
Zuccollo A; Shi C; Mastroianni R; Maitland-Toolan KA; Weisbrod RM; Zang M; Xu S; Jiang B; Oliver-Krasinski JM; Cayatte AJ; Corda S; Lavielle G; Verbeuren TJ; Cohen RA
Circulation; 2005 Nov; 112(19):3001-8. PubMed ID: 16260636
[TBL] [Abstract][Full Text] [Related]
18. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension.
Mervaala EM; Müller DN; Park JK; Schmidt F; Löhn M; Breu V; Dragun D; Ganten D; Haller H; Luft FC
Hypertension; 1999 Jan; 33(1 Pt 2):389-95. PubMed ID: 9931135
[TBL] [Abstract][Full Text] [Related]
19. P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage.
Kaergel E; Muller DN; Honeck H; Theuer J; Shagdarsuren E; Mullally A; Luft FC; Schunck WH
Hypertension; 2002 Sep; 40(3):273-9. PubMed ID: 12215466
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis.
Hong TT; Huang J; Driscoll E; Lucchesi BR
J Cardiovasc Pharmacol; 2006 Nov; 48(5):239-48. PubMed ID: 17110806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
